Publications | Flatiron Health | Tumor agnostic

Browse every publication tagged Tumor agnostic

November 2025
A pan-tumor and pan-country approach to LLM-based extraction of systemic therapies from the electronic health record
May 2023
Tumor mutational burden measurement from an FDA-approved assay and real-world overall survival on single-agent immune checkpoint inhibitors in over 8,000 patients across 24 cancer types
- Tumor agnostic
- Clinical development
May 2021
Statistical methods for pantumor analysis: models to account for tumor-level heterogeneity
- Methodology
- Tumor agnostic
April 2021
TRK fusion cancer: patient characteristics and survival analysis in the real-world setting
- Tumor agnostic
- Clinical development
October 2020
What can real-world data tell us about the prognostic significance of an emerging biomarker?
May 2020
Characteristics and outcomes of real-world patients with microsatellite instability-high solid tumors treated with pembrolizumab monotherapy after FDA approval
January 2020
Cancers with NTRK gene fusions: molecular characteristics and prognosis
- Tumor agnostic
- Clinical development
September 2019
Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset
- Tumor agnostic
- Clinical development
September 2019
Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
- Tumor agnostic
- Clinical development